

Appendix Table 1. Trial completion dates and time to journal article publication for six psychotropic drugs on clinicalstudyresults.org

	1999 or earlier	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009 or later
Aripiprazole											
Number of completed trials	0	0	3	5	10	5	4	11	8	3	3
(% published as stand-alone article) ^a			(66.7)	(40)	(40)	(100)	(75)	(54.5)	(37.5)	(100)	(0)
Average years to article publication	--	--	3	5	5	2.4	3	2	1.7	1	n/a
Olanzapine											
Number of completed trials	12	7	2	7	3	0	7	8	4	1	0
(% published as stand-alone article)	(91.7)	(100)	(100)	(85.7)	(33.3)		(28.6)	(37.5)	(0)	(100)	
Average years to article publication	2.2	2.3	4	3.5	3	--	3	3	n/a	1	--
Ziprasidone											
Number of completed trials	0	0	0	2	5	4	7	2	1	8	5
(% published as stand-alone article)				(50)	(20)	(25)	(42.9)	(100)	(0)	(0)	(0)
Average years to article publication	--	--	--	5	2	6	3.7	3	n/a	n/a	n/a
Atomoxetine											
Number of completed trials	1	2	6	6	6	7	8	12	3	0	0
(% published as stand-alone article)	(100)	(100)	(66.7)	(83.3)	(66.7)	(71.4)	(75)	(16.7)	(66.7)		
Average years to article publication	3	2	2.3	2.6	2.8	2.8	1.8	1	1	--	--
Duloxetine											
Number of completed trials	3	1	6	4	5	7	10	4	8	0	1
(% published as stand-alone article)	(0)	(100)	(66.7)	(100)	(100)	(57.1)	(90)	(75)	(62.5)		(0)
Average years to article publication	n/a	2	1.8	3	2.8	2	2.1	1.3	1.4	--	n/a
Sertraline											
Number of completed trials	4	0	3	0	5	0	2	0	2	0	0
(% published as stand-alone article)	(75)		(0)		(80)		(0)		(0)		
Average years to article publication	4.3	--	n/a/	--	1.8	--	n/a	--	n/a	--	--
All Drugs											
Number of completed trials	20	10	20	24	34	23	38	37	26	12	10
(% published as stand-alone article)	(75)	(100)	(60)	(75)	(56)	(65)	(60)	(43)	(38)	(33)	(0)

Average years to article publication	3.2	2.1	2.8	3.8	2.9	3.3	2.7	2.1	1.4	1	n/a
--------------------------------------	-----	-----	-----	-----	-----	-----	-----	-----	-----	---	-----

^a Meta-analyses and sub-set analyses published in journals and conference abstracts are not included in the percent published.

Appendix Table 2: Drug-treated participants and serious adverse events (SAEs) among ten trial summaries of clinical trials completed in 2009 or later (excluded from the published analysis)

	Number of excluded trial summaries	Number of drug-treated participants	Total number of SAEs in drug-treated participants	Number of SAEs			
				Death	Suicide, completed	Suicidal ideation, attempt, injury	New or worsened psychiatric symptoms
Aripiprazole	3	676	39	1	1	1	2
Olanzapine	0	NA	NA	NA	NA	NA	NA
Ziprasidone	5	1436	124	3	2	9	57
Atomoxetine	0	NA	NA	NA	NA	NA	NA
Duloxetine	1	657	2	0	0	0	1
Sertraline	1	157	2	0	0	1	0
All Drugs	10	2926	167	4	3	11	60